About NicOx

Profile
Pipeline
Medical Education Grants

Development
Naproxcinod
NCX 6560
Portfolio
Maximizing portfolio
R&D partnerships
NO-donating Research Platform
People
Board of Directors
Management Team
Contacts
Careers
Investor & media
Press releases
Investor relations

Fact file
Financials
Corporate governance
"Informations Réglementées"

Conferences
Home
Directions to NicOx
Site en français


NicOx fact file
Listing Segment:

Euronext Paris
: Eurolist Next Economy
FTSE Classification Economical group: non cyclical consumer goods (40)
Industrial sector: pharmaceuticals (48)
Industry sub-sector: pharmaceuticals (480)
Euroclear France code: 7413
Reuters code: NCOX.PA
Bloomberg code: COX.FP
IPO date: November 3, 1999
Gross proceeds: 33 million euros
Follow-on offering: May 21, 2001
Gross proceeds: 59 million euros
Private placement: September 30, 2004
Gross proceeds: 26 million euros
Private placement: April 28, 2006
Gross proceeds: approx. 45.5 million euros
Rights issue : February 16, 2007
Net Proceeds : 120.7 million euros
Two-step capital increase :Q4 2009
  • Private placement:
November 23, 2009 
             Net Proceeds :29.4 million euros
  • Rights issue :
December 23, 2009
             Net Proceeds :65.2 million euros
 Total Net Proceeds :94.6 million euros
Share price: Euronext
Share capital : € 14,472,823.40
Number of outstanding shares: 72,539,783
Number of voting rights as of July 31, 2010: 72,539,783
Total number of voting right
calculated on the basis of all
the shares to which voting right
are attached even if exercise
thereof is suspended:
72,539,783
Public (as of 31.12.09): 98.22%
Analyst coverage : Search based in France / UK
Shareholder structure:

To its knowledge, as of 31 December 2009, NicOx' capital structure was:
Public:
Main shareholders:

98.22%
FSI 
Oppenheimer Funds
Pfizer Overseas Pharmaceuticals
Blombank (Switzerland)
Bellevue Asset Management AG

Founding managers: 1.78%

Contact:

+33 (0)4 97 24 53 00 / communications@nicox.com